Ann: Kazia commences recruitment to GBM AGILE, page-12

Not quite ... screening does not equal enrolment.
And the study started in July 2019 so a number of patients must have been screened before paxalisib was included in the study in 2021.

Unless I misunderstand the study design, which is possible, it has 3 investigational study arms and 1 control arm.
The VAL-083 may end up with more patients as it also includes methylated patients.

For every 4 patients enrolled with either new, unmethylated GBM or recurrent GBM, I’d expect 1 patient in the paxalisib arm.